Rare diseases
Investigational molecules
Locations
Cizutamig is a protein-based, bispecific T-cell engaging antibody. It is an investigational substance, meaning it has no marketing authorisation in the product records and is not yet approved as a medicine.[1] The substance is supplied by Candid Therapeutics Inc. and is also known simply as cizutamig.
Cizutamig is designed to bind to two targets: BCMA on certain immune cells and CD3 on T cells. By linking these cells, it aims to direct T cells to attack BCMA-expressing cells. The trial data do not provide further details on the mechanism, but the primary focus is on safety in patients with immune-mediated inflammatory diseases.[1]
The SPLENDID trial is studying cizutamig in four severe, treatment-refractory immune-mediated inflammatory diseases:
Cizutamig is given as a solution for infusion, administered by intravenous infusion.[1]
One clinical trial, the SPLENDID trial, is investigating cizutamig. It is a Phase 1, open-label study that has been authorised. The trial plans to enrol 12 participants with severe, treatment-refractory immune-mediated inflammatory diseases.[1]
The primary outcome measures safety, specifically the incidence and severity of cytokine release syndrome (CRS), immune cell associated neurotoxicity syndrome (ICANS), and treatment-emergent adverse events until 28 days after the last administration of cizutamig.[1]
The trial is designed to assess safety, including cytokine release syndrome and immune cell associated neurotoxicity syndrome, but no detailed side effect data are available from the registry record.[1]
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
